Synaptogenix, Inc.

NasdaqCM:SNPX Stock Report

Market Cap: US$4.1m

Synaptogenix Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Alan Tuchman

Chief executive officer

US$303.3k

Total compensation

CEO salary percentage73.2%
CEO tenure4yrs
CEO ownership0.1%
Management average tenure8.3yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

We Think Synaptogenix (NASDAQ:SNPX) Can Afford To Drive Business Growth

Sep 20
We Think Synaptogenix (NASDAQ:SNPX) Can Afford To Drive Business Growth

Companies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In Growth

May 10
Companies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In Growth

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

Nov 17

Synaptogenix (NASDAQ:SNPX) Is In A Good Position To Deliver On Growth Plans

Oct 05
Synaptogenix (NASDAQ:SNPX) Is In A Good Position To Deliver On Growth Plans

Synaptogenix: The Next Big Thing In Alzheimer's

Jun 16

Synaptogenix provides update on phase 2b Alzheimer's disease trial

Jun 09

We're Keeping An Eye On Synaptogenix's (NASDAQ:SNPX) Cash Burn Rate

Jun 09
We're Keeping An Eye On Synaptogenix's (NASDAQ:SNPX) Cash Burn Rate

CEO Compensation Analysis

How has Alan Tuchman's remuneration changed compared to Synaptogenix's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$9m

Jun 30 2024n/an/a

-US$3m

Mar 31 2024n/an/a

-US$12m

Dec 31 2023US$303kUS$222k

-US$14m

Sep 30 2023n/an/a

-US$8m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023n/an/a

-US$4m

Dec 31 2022US$750kUS$222k

-US$6m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$14m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$1mUS$222k

-US$13m

Sep 30 2021n/an/a

-US$14m

Jun 30 2021n/an/a

-US$15m

Mar 31 2021n/an/a

-US$16m

Dec 31 2020US$184kUS$184k

-US$15m

Sep 30 2020n/an/a

-US$12m

Dec 31 2019US$36kUS$36k

-US$15m

Compensation vs Market: Alan's total compensation ($USD303.35K) is below average for companies of similar size in the US market ($USD651.40K).

Compensation vs Earnings: Alan's compensation has been consistent with company performance over the past year.

CEO

Alan Tuchman (77 yo)

4yrs

Tenure

US$303,347

Compensation

Dr. Alan J. Tuchman M.D., MBA(FAAN), serves as the Chief Executive Officer at Synaptogenix, Inc. (formerly, Neurotrope Bioscience, Inc.), since December 2020 and has been its Director since December 02, 20...

Leadership Team

NamePositionTenureCompensationOwnership
Alan Tuchman
CEO & Director4yrsUS$303.35k0.097%
$ 4.0k
Daniel Alkon
President8.3yrsUS$375.00k0.10%
$ 4.3k
Robert Weinstein
CFO, Executive VP11.5yrsUS$568.92k0.098%
$ 4.0k

8.3yrs

Average Tenure

77yo

Average Age

Experienced Management: SNPX's management team is seasoned and experienced (8.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Alan Tuchman
CEO & Director4yrsUS$303.35k0.097%
$ 4.0k
Daniel Alkon
President4yrsUS$375.00k0.10%
$ 4.3k
Joshua Silverman
Independent Chairman of the Board8.3yrsUS$254.94k0.11%
$ 4.6k
George Perry
Chairman of the Scientific Advisory Board3.3yrsUS$449.77kno data
Marwan Sabbagh
Member of Scientific Advisory Boardno datano datano data
William Singer
Independent Vice-Chairman of the Board5.3yrsUS$114.94k0.097%
$ 4.0k
Jonathan Schechter
Independent Director6yrsUS$74.94k0.080%
$ 3.3k
Bruce Bernstein
Independent Director8.1yrsUS$74.94k0.081%
$ 3.3k
Paul Coleman
Member of Scientific Advisory Boardno datano datano data
Robert Howard
Member of Scientific Advisory Boardno datano datano data
Zaven Khachaturian
Member of Scientific Advisory Boardno datano datano data

5.3yrs

Average Tenure

66yo

Average Age

Experienced Board: SNPX's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 16:05
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Synaptogenix, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group